ANIXAnixa Biosciences
About Anixa Biosciences
Anixa Biosciences (NASDAQ:ANIX) is a biotechnology firm focused on harnessing the body's immune system to fight cancer. Dedicated to developing a range of innovative treatments and vaccines, Anixa's operations span from early research to clinical trials. The company is especially known for its work in developing a cancer vaccine technology aimed at preventing breast cancer, as well as chimeric endocrine receptor T-cell (CER-T) technology targeting prostate cancer. With a commitment to advancing healthcare, Anixa's objectives include bringing groundbreaking immunotherapies and vaccines to market, offering new hope in the fight against cancer.
What is ANIX known for?
Snapshot
Public US
Ownership
1982
Year founded
12
Employees
San Jose, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
San Jose, US
Produtos e/ou serviços de Anixa Biosciences
- Breast cancer vaccine development focused on preventing the recurrence and development of triple-negative breast cancer, utilizing immunotherapy approaches.
- Ovarian cancer vaccine, leveraging the same technology platform as the breast cancer vaccine for prevention and inhibitory growth of ovarian tumors.
- CAR-T technology for solid tumors, innovating cellular therapy to target and destroy cancer cells in various solid tumor types.
- Cchek™, a proprietary AI-based platform for early cancer detection, using machine learning to analyze simple blood tests for multiple cancer types.
- Prostate cancer therapy, focusing on a novel approach to treat early-stage prostate cancer non-invasively, aiming to reduce side effects associated with current treatments.
- Collaboration with Cleveland Clinic on developing vaccines, reflecting a strategic partnership to advance prevention therapies for various cancers.
equipe executiva do Anixa Biosciences
- Dr. Amit Kumar Ph.D.CEO, Chairman & Co-Chair of CBAB
- Mr. Michael J. Catelani CPA, MBAPresident, COO, CFO & Corporate Secretary
- Dr. Pamela D. Garzone Ph.D.Chief Development Officer & Chair Breast Cancer Clinical Advisory Board